The role of pemetrexed in recurrent epithelial ovarian cancer: A scoping review | Zendy

Michael Roche | Zendy; Laura Parisi | Zendy; Linda Li | Zendy; Amy Knehans | Zendy; Rébécca Phaëton | Zendy; Joshua P. Kesterson | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

The role of pemetrexed in recurrent epithelial ovarian cancer: A scoping review

Author(s) -

Michael Roche,

Laura Parisi,

Linda Li,

Amy Knehans,

Rébécca Phaëton,

Joshua P. Kesterson

Publication year - 2018

Publication title -

oncology reviews

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.637

H-Index - 21

eISSN - 1970-5565

pISSN - 1970-5557

DOI - 10.4081/oncol.2018.346

Subject(s) - pemetrexed , medicine , ovarian cancer , oncology , epithelial ovarian cancer , gynecologic cancer , mesothelioma , disease , cancer , chemotherapy , pathology , cisplatin

Ovarian cancer is the leading cause of mortality among gynecologic malignancies, with most cases diagnosed at an advanced stage. Despite an initial response, most develop a recurrence and subsequent resistance to standard therapies. Pemetrexed (Alimta) is a new generation multi-targeted antifolate initially approved for the treatment of malignant pleural mesothelioma. In recent years, it has shown promise in the treatment of recurrent epithelial ovarian cancer. In this review, we outline the current literature and discuss the future of pemetrexed in the setting of recurrent epithelial ovarian cancer.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research